Introduction
Scleroderma is a chronic autoimmune disease in which the body produces excessive connective tissue, especially collagen, leading to hardening and thickening of the skin and, in some forms, involvement of internal organs and blood vessels. The core problem is not simply “stiff skin,” but a disease process that combines immune dysregulation, small-vessel injury, and abnormal tissue repair. These mechanisms drive progressive fibrosis, meaning the accumulation of scar-like tissue where normal tissue architecture should remain flexible and functional.
The condition mainly affects the skin, microvasculature, and connective tissues, but depending on the form of scleroderma it can also involve the digestive tract, lungs, heart, kidneys, and musculoskeletal system. Understanding scleroderma requires looking at how immune signals, vascular damage, and fibroblast activation interact to alter normal tissue maintenance.
The Body Structures or Systems Involved
Scleroderma primarily involves the connective tissue of the body. Connective tissue provides structural support and includes collagen, elastin, and the cells that produce and remodel these materials. In a healthy state, collagen is continuously synthesized and broken down in a balanced way, allowing tissues to remain strong without becoming rigid.
The skin is the most visible site of involvement. The dermis, which contains collagen fibers, fibroblasts, blood vessels, and immune cells, normally allows the skin to stay supple and elastic. In scleroderma, this layer becomes thickened and less compliant because collagen accumulates in excess and tissue remodeling becomes abnormal.
The blood vessels are another central target. Small arteries and arterioles normally regulate blood flow by adjusting vessel diameter and responding to local oxygen needs. In scleroderma, these vessels are damaged, narrowed, and less able to dilate appropriately. This vascular dysfunction contributes to reduced tissue perfusion and chronic ischemic stress.
In systemic forms of the disease, internal organs may be involved. The lungs can develop interstitial fibrosis or vascular remodeling in the pulmonary circulation. The esophagus and intestines may be affected by smooth muscle dysfunction and fibrosis of the supporting tissue, altering motility. The kidneys can be injured by severe vascular narrowing, and the heart may develop fibrosis in the myocardium or conduction system. These organs depend on delicate tissue architecture, so even modest fibrosis can significantly disrupt function.
How the Condition Develops
Scleroderma develops through a multi-step process that links immune activation, endothelial injury, and fibroblast overactivity. The sequence is not fully identical in every patient, but the dominant pattern is consistent: the immune system becomes abnormally active, blood vessel lining cells are injured, and repair pathways remain switched on long after they should have stopped.
The process often begins with endothelial dysfunction, meaning damage to the cells that line small blood vessels. These cells regulate vascular tone, clotting balance, and leukocyte trafficking. When they are injured, they release inflammatory mediators and lose their normal ability to maintain vessel flexibility. The vessels then become more reactive and more prone to narrowing.
At the same time, the immune system generates persistent signals that promote tissue remodeling. T lymphocytes, B lymphocytes, macrophages, and cytokines such as transforming growth factor beta are involved in the abnormal signaling network. These mediators stimulate fibroblasts, the cells responsible for making collagen and other matrix proteins. In healthy tissue, fibroblasts help repair injury and then return to a resting state. In scleroderma, they remain activated and behave as though the tissue is constantly being repaired.
This leads to excess extracellular matrix deposition. Collagen accumulates in the dermis and in organ tissues, gradually replacing normal cellular and elastic structures with denser fibrotic material. The same disease process also affects small blood vessels, which may develop intimal thickening, luminal narrowing, and abnormal endothelial repair. As blood flow worsens, tissues experience chronic low-grade ischemia, which can further reinforce fibrosis and dysfunction.
These changes do not occur in isolation. Fibrosis, vascular injury, and immune activation amplify one another. Reduced perfusion can increase tissue stress and drive additional inflammatory signaling. Inflammatory cytokines can activate fibroblasts more strongly. Fibrotic tissue can compress vessels and reduce oxygen delivery. The disease therefore behaves as a self-perpetuating cycle rather than a single isolated lesion.
Structural or Functional Changes Caused by the Condition
The defining structural change in scleroderma is fibrosis. Collagen fibers become denser and more tightly packed, and normal tissue spaces are reduced. In the skin, this makes the tissue thicker, firmer, and less distensible. Hair follicles, sweat glands, and other skin appendages may function less effectively because the surrounding matrix becomes abnormal.
In the vasculature, structural changes include narrowing of small arteries, thickening of the vessel wall, and impaired endothelial function. These changes limit the ability of blood vessels to deliver oxygen and nutrients under changing conditions. The result is not only poor perfusion but also a tendency toward exaggerated vasospasm and chronic circulatory instability in affected regions.
Functional consequences depend on the tissue involved. In the lungs, fibrosis reduces the compliance of the interstitial tissue, making gas exchange less efficient. If pulmonary blood vessels are involved, vascular resistance can increase, affecting pressure in the pulmonary circulation. In the gastrointestinal tract, fibrosis and smooth muscle dysfunction can reduce peristaltic movement, so transit becomes slower and coordination of digestive motion is disrupted.
Because connective tissue underlies many organ systems, scleroderma alters mechanical properties as much as it alters biochemical function. Tissues become less elastic, more rigid, and less able to accommodate stress. This mechanical change is a major reason the disease can affect movement, circulation, organ expansion, and normal tissue repair.
Factors That Influence the Development of the Condition
The exact cause of scleroderma is not known, but development appears to require a combination of genetic susceptibility and environmental or biologic triggers. Certain inherited variants influence immune regulation, antibody formation, and connective tissue responses, making some individuals more likely to develop the disease. These genes do not cause scleroderma on their own; rather, they shape how the immune system and fibroblasts respond to triggers.
Immune system activity is central to the disease mechanism. Many patients show autoimmune features, including autoantibodies and abnormal activation of immune cells. Autoimmunity can sustain endothelial injury and fibroblast stimulation through chronic cytokine release. This does not mean scleroderma is caused by a single autoimmune target. Instead, it reflects a broader failure of immune tolerance and regulation.
Environmental exposures may influence disease initiation or progression in susceptible people. Certain occupational exposures, repeated microvascular injury, and some chemical agents have been associated with increased risk in research settings. These factors are thought to act by damaging endothelial cells or altering immune signaling, although not every exposure leads to disease.
Hormonal and sex-related factors may also contribute. Scleroderma occurs more often in women, suggesting that sex hormones, immune differences, or genetic and epigenetic factors linked to sex may affect disease susceptibility. The biological reason for this pattern is not fully resolved, but it likely reflects differences in immune regulation rather than a purely hormonal disorder.
Infections have been studied as possible triggers because some pathogens can activate immune pathways or mimic host antigens, but no single infectious cause explains the disease. The most useful way to think about these influences is that they alter immune tone, vascular integrity, and tissue repair behavior in a person who is already biologically vulnerable.
Variations or Forms of the Condition
Scleroderma is usually divided into localized and systemic forms. Localized scleroderma, sometimes called morphea, primarily affects the skin and sometimes the tissue beneath it. The immune and fibrotic processes remain largely confined to a limited area, so internal organs are usually not involved. The underlying biology still involves abnormal collagen deposition, but the disease is restricted in distribution.
Systemic sclerosis is the form that can involve internal organs and blood vessels more broadly. It is often categorized by how much skin is affected. Limited cutaneous disease tends to involve areas distal to the elbows and knees and the face, with a slower cutaneous spread and a greater emphasis on vascular and late organ involvement. Diffuse cutaneous disease affects larger areas of skin more quickly and is more likely to show early internal organ involvement. These patterns reflect differences in how aggressively the immune-fibrotic process spreads through tissues.
Another useful distinction is the degree of vascular predominance versus fibrotic predominance. Some patients show marked vasculopathy with less extensive fibrosis, while others develop rapid collagen accumulation in skin and organs. This variability may reflect differences in cytokine signaling, autoantibody profiles, and fibroblast responsiveness.
The disease can also vary in tempo. In some people, progression is relatively slow and remains limited to the skin and peripheral vessels. In others, the immune and vascular injury progresses enough to involve lungs, kidneys, or the gastrointestinal tract within a shorter time frame. These differences are not superficial variations; they arise from different intensities and distributions of the same core pathologic mechanisms.
How the Condition Affects the Body Over Time
Over time, scleroderma can create a cumulative burden of fibrosis and vascular injury. As collagen continues to accumulate, tissues lose flexibility and normal architecture. This can make skin, blood vessels, and organ walls less able to respond to changing physiologic demands. The longer the cycle of injury and repair continues, the more difficult it becomes for affected tissues to return to normal structure.
Chronic vascular dysfunction can produce ongoing tissue hypoperfusion. When oxygen delivery remains suboptimal, cells operate under stress and may release additional mediators that support inflammation or remodeling. Repeated ischemia-reperfusion injury can intensify endothelial damage. In this way, vascular disease is not merely a side effect of fibrosis; it can help drive disease persistence.
Internal organs may gradually lose reserve. Fibrosis in the lungs can reduce gas exchange efficiency. Fibrosis in the heart can interfere with electrical conduction or relaxation. Fibrosis and dysmotility in the digestive tract can alter absorption and coordinated movement. The kidney, if affected by severe vascular disease, may respond to reduced renal perfusion with maladaptive neurohormonal activation that further stresses the circulation.
The body can attempt partial compensation. For example, tissues may increase local signaling to improve blood flow, and organs may adapt to reduced compliance or altered motility. However, these responses are often incomplete because the fundamental problem is structural remodeling. Once normal tissue has been replaced by fibrotic matrix, function cannot be fully restored simply by increasing activity in the remaining cells.
Conclusion
Scleroderma is a connective tissue disease defined by the combination of autoimmunity, small-vessel injury, and progressive fibrosis. It affects the skin most visibly, but its underlying biology can involve blood vessels and multiple internal organs. The hallmark process is persistent activation of repair pathways, especially fibroblast-driven collagen deposition, which distorts normal tissue structure and function.
Understanding scleroderma means understanding how immune dysregulation and vascular damage can shift the body from controlled healing into chronic scarring. The disease is not one single lesion but a coordinated pathologic process that alters tissue mechanics, circulation, and organ function over time. That mechanism-based view provides the foundation for understanding its later manifestations, diagnosis, and treatment.